Research - Conatus Pharmaceuticals (CNAT) will release the combined results from 3 phase 1 and 2 studies on Thursday after the bell. CNAT is up 60% from our suggestion to get long the stock this Fall at $6.00.
Research - Solithromycin proves non-inferior to moxifloxacin in phase 3 SOLITAIRE-ORAL trial, meets endpoints endorsed by both U.S. and E.U. regulators. Enrollment update for SOLITAIRE-IV is expected in … Continue Reading